Abstract
Abstract:Psoriasis is common, affecting about 2–3% of the population, and has major effects on patients’ quality of life. Psoriasis varies in its manifestations and in how patients perceive the condition. Successful treatment involves addressing the clinical, psychological, and social aspects of the disease. Treatment options include topical agents, phototherapy and systemic treatment. Topical treatments are only practical for a fairly limited area of involvement. Phototherapy is practical for larger areas of involvement, but office phototherapy treatments are inconvenient. Traditional systemic medications are limited by side effects. New biologic agents that target specific components of the immune system are the most recent addition to our list of medications and provide higher efficacy with an improved safety profile, albeit at a higher cost.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001;15:16–17.RaychaudhuriSP]]FarberEMThe prevalence of psoriasis in the world.J Eur Acad Dermatol Venereol20011516-172. Rapp SR, Feldman SR, Exum ML, et al. Poriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401–407.RappSR]]FeldmanSR]]ExumML&etal;Poriasis causes as much disability as other major medical diseases.J Am Acad Dermatol199941401-4073. Gulliver W. Long-term prognosis in patients with psoriasis. Br J Dermatol 2008;159(suppl 2):2–9.GulliverWLong-term prognosis in patients with psoriasis.Br J Dermatol20081592-94. Gottlieb AB, Dann F, Menter A. Psoriasis and the metabolic syndrome. J Drugs Dermatol 2008;7:563–572.GottliebAB]]DannF]]MenterAPsoriasis and the metabolic syndrome.J Drugs Dermatol20087563-5725. Shelling ML, Federman DG, Prodanovich S, et al. Psoriasis and vascular disease: an unsolved mystry. Am J Med 2008;121:360–365.ShellingML]]FedermanDG]]ProdanovichS&etal;Psoriasis and vascular disease: an unsolved mystry.Am J Med2008121360-3656. Fortune DG, Richards HL, Griffiths CE. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol Clin 2005;23:681–694.FortuneDG]]RichardsHL]]GriffithsCEPsychologic factors in psoriasis: consequences, mechanisms, and interventions.Dermatol Clin200523681-6947. Ginsburg IH, Link BG. Feelings of stigmatization in patients with psoriasis. J Am Acad Dermatol 1989;20:53–63.GinsburgIH]]LinkBGFeelings of stigmatization in patients with psoriasis.J Am Acad Dermatol19892053-638. Elder JT, Nair RP, Guo SW, et al. The genetics of psoriasis. Arch Dermatol 1994;130:216–224.ElderJT]]NairRP]]GuoSW&etal;The genetics of psoriasis.Arch Dermatol1994130216-2249. Hüffmeier U, Lascorz J, Traupe H, et al. Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris. J Invest Dermatol 2005;125:906–912.HüffmeierU]]LascorzJ]]TraupeH&etal;Systematic linkage disequilibrium analysis of SLC12A8 at PSORS5 confirms a role in susceptibility to psoriasis vulgaris.J Invest Dermatol2005125906-91210. Schön MP, Boehncke WH. Psoriasis. N Engl J Med 2005;352:1899–1912.SchönMP]]BoehnckeWHPsoriasis.N Engl J Med20053521899-191211. Krueger JG, Bowcock A. Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005;64(suppl 2):ii30–ii36.KruegerJG]]BowcockAPsoriasis pathophysiology: current concepts of pathogenesis.Ann Rheum Dis200564ii30-ii3612. Andressen C, Henseler T. [Inheritance of psoriasis Analysis of 2035 family histories]. Hautarzt 1982;33:214–217 [in German].13. Baker BS, Swain AF, Fry L, et al. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Dermatol 1984;110:555–564.BakerBS]]SwainAF]]FryL&etal;Epidermal T lymphocytes and HLA-DR expression in psoriasis.Br J Dermatol1984110555-56414. Menter A, Griffiths CE. Current and future management of psoriasis. Lancet 2007;370:272–284.MenterA]]GriffithsCECurrent and future management of psoriasis.Lancet2007370272-28415. Koo J, Khera P. Update on the mechanisms and efficacy of biological therapies for psoriasis. J Dermatol Sci 2005;38:75–87.KooJ]]KheraPUpdate on the mechanisms and efficacy of biological therapies for psoriasis.J Dermatol Sci20053875-8716. Christophers E. Psoriasis—epidemiology and clinical spectrum. Clin Exp Dermatol 2001;26:314–320.ChristophersEPsoriasis—epidemiology and clinical spectrum.Clin Exp Dermatol200126314-32017. Weiss G, Shemer A, Trau H. The Koebner phenomenon: review of the literature. J Eur Acad Dermatol Venereol 2002;16:241–248.WeissG]]ShemerA]]TrauHThe Koebner phenomenon: review of the literature.J Eur Acad Dermatol Venereol200216241-24818. Kvedar JC, Baden HP. Nail changes in cutaneous disease. Semin Dermatol 1991;10:65–70.KvedarJC]]BadenHPNail changes in cutaneous disease.Semin Dermatol19911065-7019. Telfer NR, Chalmers RJ, Whale K, et al. The role of streptococcal infection in the initiation of guttate psoriasis. Arch Dermatol 1992;128:39–42.TelferNR]]ChalmersRJ]]WhaleK&etal;The role of streptococcal infection in the initiation of guttate psoriasis.Arch Dermatol199212839-4220. Whyte HJ, Baughman RD. Acute guttate psoriasis and streptococcal infection. Arch Dermatol 1964;89:350–356.WhyteHJ]]BaughmanRDAcute guttate psoriasis and streptococcal infection.Arch Dermatol196489350-35621. Baker H, Ryan TJ. Generalized pustular psoriasis. A clinical and epidemiological study of 104 cases. Br J Dermatol 1968;80:771–793.BakerH]]RyanTJGeneralized pustular psoriasis. A clinical and epidemiological study of 104 cases.Br J Dermatol196880771-79322. Kopp T, Karlhofer F, Szépfalusi Z, et al. Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type. Br J Dermatol 2004;151:912–916.KoppT]]KarlhoferF]]SzépfalusiZ&etal;Successful use of acitretin in conjunction with narrowband ultraviolet B phototherapy in a child with severe pustular psoriasis, von Zumbusch type.Br J Dermatol2004151912-91623. Gudjonsson JE, Elder JT. Psoriasis in Fitzpatricks’s Dermatology in General Medicine. 2007;Vol 1, ed 7, pp 169–193.24. van de Kerkhof PC. Therapeutic strategies: rotational therapy and combinations. Clin Exp Dermatol 2001;26:356–361.van de KerkhofPCTherapeutic strategies: rotational therapy and combinations.Clin Exp Dermatol200126356-36125. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280–284.KruegerG]]KooJ]]LebwohlM&etal;The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.Arch Dermatol2001137280-28426. Savary J, Ortonne JP, Aractingi S. The right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments. J Eur Acad Dermatol Venereol 2005;19(suppl 3):14–17.SavaryJ]]OrtonneJP]]AractingiSThe right dose in the right place: an overview of current prescription, instruction and application modalities for topical psoriasis treatments.J Eur Acad Dermatol Venereol20051914-1727. Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487–498; quiz 499–502.28. Ramsay CA. Management of psoriasis with calcipotriol used as monotherapy. J Am Acad Dermatol 1997;37:S53–S54.RamsayCAManagement of psoriasis with calcipotriol used as monotherapy.J Am Acad Dermatol199737S53-S5429. Van de Kerkhof PCM. Dithranol treatment for psoriasis: after 75 years, still going strong. Eur J Dermatol 1991;1:79–88.Van de KerkhofPCMDithranol treatment for psoriasis: after 75 years, still going strong.Eur J Dermatol1991179-8830. Hönigsmann H. Phototherapy for psoriasis. Clin Exp Dermatol 2001;26:343–350.HönigsmannHPhototherapy for psoriasis.Clin Exp Dermatol200126343-35031. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999;189:711–718.OzawaM]]FerencziK]]KikuchiT&etal;312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions.J Exp Med1999189711-71832. van Weelden H, De La Faille HB, Young E, et al. A new development in UVB phototherapy of psoriasis. Br J Dermatol 1988;119:11–19.van WeeldenH]]De La FailleHB]]YoungE&etal;A new development in UVB phototherapy of psoriasis.Br J Dermatol198811911-1933. Green C, Ferguson J, Lakshmipathi T, et al. 311 nm UVB phototherapy— an effective treatment for psoriasis. Br J Dermatol 1988;119:691–696.GreenC]]FergusonJ]]LakshmipathiT&etal;311 nm UVB phototherapy— an effective treatment for psoriasis.Br J Dermatol1988119691-69634. Yones SS, Palmer RA, Garibaldinos TT, et al. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol 2006;142:836–842.YonesSS]]PalmerRA]]GaribaldinosTT&etal;Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy.Arch Dermatol2006142836-84235. Passeron T, Ortonne JP. Use of the 308-nm excimer laser for psoriasis and vitiligo. Clin Dermatol 2006;24:33–42.PasseronT]]OrtonneJPUse of the 308-nm excimer laser for psoriasis and vitiligo.Clin Dermatol20062433-4236. Griffiths CE, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1–125.GriffithsCE]]ClarkCM]]ChalmersRJ&etal;A systematic review of treatments for severe psoriasis.Health Technol Assess200041-12537. Roenigk HH Jr, Auerbach R, Maibach HI, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988;19(1 pt 1):145–156.RoenigkHHJr]]AuerbachR]]MaibachHI&etal;Methotrexate in psoriasis: revised guidelines.J Am Acad Dermatol1988191 pt 1145-15638. Strober BE, Menon K. Folate supplementation during methotrexate therapy for patients with psoriasis. J Am Acad Dermatol 2005;53:652–659.StroberBE]]MenonKFolate supplementation during methotrexate therapy for patients with psoriasis.J Am Acad Dermatol200553652-65939. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. J Am Acad Dermatol 2001;45:649–661; quiz 662–644.40. Kazlow Stern D, Tripp JM, Ho VC, et al. The use of systemic immune moderators in dermatology: an update. Dermatol Clin 2005;23:259–300.Kazlow SternD]]TrippJM]]HoVC&etal;The use of systemic immune moderators in dermatology: an update.Dermatol Clin200523259-30041. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664–1675.NickoloffBJ]]NestleFORecent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.J Clin Invest20041131664-167542. Rigby WF. Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications? Semin Arthritis Rheum 2005;34(5 suppl 1):1–2.RigbyWFDistinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?Semin Arthritis Rheum2005341-243. Leonardi CL. Efalizumab: an overview. J Am Acad Dermatol 2003;49:S98–S104.LeonardiCLEfalizumab: an overview.J Am Acad Dermatol200349S98-S10444. Sterry W, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol 2004;151(suppl 69):3–17.SterryW]]BarkerJ]]BoehnckeWH&etal;Biological therapies in the systemic management of psoriasis: International Consensus Conference.Br J Dermatol20041513-1745. Van de Kerkhof PC. Consistent control of psoriasis by continuous long-term therapy: the promise of biological treatments. J Eur Acad Dermatol Venereol 2006;20:639–650.Van de KerkhofPCConsistent control of psoriasis by continuous long-term therapy: the promise of biological treatments.J Eur Acad Dermatol Venereol200620639-65046. Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558–566.SauratJH]]StinglG]]DubertretL&etal;Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION).Br J Dermatol2008158558-56647. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580–592.KruegerGG]]LangleyRG]]LeonardiC&etal;A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.N Engl J Med2007356580-59248. Shaker OG, Moustafa W, Essmat S, et al. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem 2006;39:119–125.ShakerOG]]MoustafaW]]EssmatS&etal;The role of interleukin-12 in the pathogenesis of psoriasis.Clin Biochem200639119-125
